Abstract:Senolytics are a class of drugs that selectively clear senescent cells (SC). The first senolytic drugs Dasatinib, Quercetin, Fisetin, and Navitoclax were discovered using a hypothesis‐driven approach. SC accumulate with aging and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality, and health expenditures. The most deleterious SC are resistant to apoptosis and have up‐regulation of anti‐apoptotic pathways which defend SC against their own inflammatory senescence‐associated secretory phenotype (SASP), allowing them to survive, despite killing neighboring cells. Senolytics transiently disable these SCAPs, causing apoptosis of those SC with a tissue‐destructive SASP. Because SC take weeks to re‐accumulate, senolytics can be administered intermittently – a "hit‐and‐run" approach. In pre‐clinical models, senolytics delay, prevent, or alleviate frailty, cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic, and skin disorders as well as complications of organ transplantation, radiation, and cancer treatment. As anticipated for agents targeting the fundamental aging mechanisms that are "root cause" contributors to multiple disorders, potential uses of senolytics are protean, potentially alleviating over 40 conditions in preclinical studies, opening a new route for treating age‐related dysfunction and diseases. Early pilot trials of senolytics suggest they decrease senescent cells, reduce inflammation, and alleviate frailty in humans. Clinical trials for diabetes, idiopathic pulmonary fibrosis, Alzheimer's disease, COVID‐19, osteoarthritis, osteoporosis, eye diseases, and bone marrow transplant and childhood cancer survivors are underway or beginning. Until such studies are done, it is too early for senolytics to be used outside of clinical trials.

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation

Design and optimization of piperlongumine analogs as potent senolytics

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

Development of novel flavonoid senolytics through phenotypic drug screening and drug design

Overview of piperlongumine analogues and their therapeutic potential

Emerging senolytic agents derived from natural products

Identification of Piperlongumine (PL) as a new E3 ligase ligand to induce targeted protein degradation

Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21 WAF1/CIP1 proteasomal degradation in senescent cells

An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis

Repurposing the plant-derived compound apigenin for senomorphic effect in antiaging pipelines

Discovery of a Novel Piperlongumine Analogue As a Microtubule Polymerization Inhibitor with Potent Anti-Angiogenic and Anti-Metastatic Efficacy.

Senolytic drugs: from discovery to translation

Discovery and Repurposing of Multi-Target Senolytics through Structure-Based Virtual Screening

Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties

Piperlongumine Suppresses Proliferation of Human Oral Squamous Cell Carcinoma through Cell Cycle Arrest, Apoptosis and Senescence

Novel Non-Trimethoxylphenyl Piperlongumine Derivatives Selectively Kill Cancer Cells.

Senolytic Therapy Enabled by Senescent Cell‐Sensitive Biomimetic Melanin Nano‐senolytics

Discovery, development, and future application of senolytics: theories and predictions

Piperlongumine Analogue L50377 Induces Pyroptosis Via ROS Mediated NF-κB Suppression in Non-Small-cell Lung Cancer.

Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells Via ROS Regulation